相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
Odelia Cooper et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease
Hanna R. Kemeny et al.
CLINICAL CANCER RESEARCH (2020)
Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
Valentine Suteau et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT-20 and TtT/GF by affecting expression of MMP-14 and ADAM12
Zhuo Zhang et al.
FEBS OPEN BIO (2020)
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
Nazanin Majd et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The activation of G protein-coupled receptor 30 increases pro-opiomelanocortin gene expression through cAMP/PKA/NR4A pathway in mouse pituitary corticotroph AtT-20 cells
Shinobu Takayasu et al.
NEUROSCIENCE LETTERS (2020)
Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review
Zachary K. Christian et al.
INTERDISCIPLINARY NEUROSURGERY-ADVANCED TECHNIQUES AND CASE MANAGEMENT (2020)
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
Donato Iacovazzo et al.
ENDOCRINE (2020)
Advances in the medical treatment of Cushing's syndrome
Richard A. Feelders et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA
Chitra Choudhary et al.
ENDOCRINE PRACTICE (2019)
111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Augmented Reality in Transsphenoidal Surgery
Barbara Carl et al.
WORLD NEUROSURGERY (2019)
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
G. Giuffrida et al.
ENDOCRINE CONNECTIONS (2019)
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Breelyn A. Wilky
IMMUNOLOGICAL REVIEWS (2019)
Medical Management of Cushing Disease
Nicholas A. Tritos et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2019)
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial
Rafael L. Batista et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness
Pedro Marques et al.
ENDOCRINE-RELATED CANCER (2019)
Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas
Dongyun Zhang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: A systematic study
Ricarda Hannen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary Adenoma: Case Report and Literature Review
Yong Wang et al.
WORLD NEUROSURGERY (2019)
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
Gerald Raverot et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
Matthew P. Salomon et al.
CLINICAL CANCER RESEARCH (2018)
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
Ann McCormack et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Combined effects of resveratrol and radiation in GH3 and TtT/GF pituitary adenoma cells
B. Voellger et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy
Peng-fei Wang et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
EGFR-TKIs resistance via EGFR-independent signaling pathways
Qian Liu et al.
MOLECULAR CANCER (2018)
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Hitisha K. Patel et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Expression of Matrix Metalloproteinase-9, Pituitary Tumor Transforming Gene, High Mobility Group A 2, and Ki-67 in Adrenocorticotropic Hormone-Secreting Pituitary Tumors and Their Association with Tumor Recurrence
Xiaohai Liu et al.
WORLD NEUROSURGERY (2018)
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
Andre Lacroix et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab
Andrew L. Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line
Carmelina Di Pasquale et al.
ENDOCRINE (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endoscopic Versus Microscopic Transsphenoidal Surgery in the Treatment of Pituitary Adenoma: A Systematic Review and Meta-Analysis
Aijun Li et al.
WORLD NEUROSURGERY (2017)
Overview of the 2017 WHO Classification of Pituitary Tumors
Ozgur Mete et al.
ENDOCRINE PATHOLOGY (2017)
Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients
Pia Burman et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists
Y. Greenman et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Cabergoline treatment for recurrent Cushing's disease during pregnancy
Afif Nakhleh et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2016)
Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas
Junwen Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro
Shi-qi Cheng et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Yu Mei et al.
ONCOTARGET (2016)
Microsatellite instability: an update
Hiroyuki Yamamoto et al.
ARCHIVES OF TOXICOLOGY (2015)
Recurrent gain-of-function USP8 mutations in Cushing's disease
Zeng-Yi Ma et al.
CELL RESEARCH (2015)
Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy
Leonardo Vieira Neto et al.
CLINICAL ENDOCRINOLOGY (2015)
ErbB Receptor-Driven Prolactinomas Respond to Targeted Lapatinib Treatment in Female Transgenic Mice
Xiaohai Liu et al.
ENDOCRINOLOGY (2015)
Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas
Guliz Demirelli Gultekin et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications
Christian P. Miermeister et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
Mutations in the deubiquitinase gene USP8 cause Cushing's disease
Martin Reincke et al.
NATURE GENETICS (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Dopamine 2 and Somatostatin 1-5 Receptors Coexpression in Clinically Non-Functioning Pituitary Adenomas
F. Gabalec et al.
PHYSIOLOGICAL RESEARCH (2015)
The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
Eric Monsalves et al.
ENDOCRINE-RELATED CANCER (2014)
Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease
Susan M. Webb et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies
Laura Chinezu et al.
HUMAN PATHOLOGY (2014)
High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM): A Case Series
Brad E. Zacharia et al.
NEUROSURGERY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
Jan Komor et al.
PITUITARY (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors
Odelia Cooper et al.
ENDOCRINE (2014)
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up
Jacqueline Trouillas et al.
ACTA NEUROPATHOLOGICA (2013)
mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features
Emir Ahmed Sajjad et al.
ENDOCRINE PATHOLOGY (2013)
Bisphenol S Disrupts Estradiol-Induced Nongenomic Signaling in a Rat Pituitary Cell Line: Effects on Cell Functions
Rene Vinas et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2013)
Carcinogenicity and hormone studies with the tissue-selective estrogen receptor modulator bazadoxifene
David J. Wright et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas
Erica C. Garcia et al.
PITUITARY (2013)
Resveratrol decreases B-cell lymphoma-2 expression and viability in GH3 pituitary adenoma cells of the rat
Benjamin Voellger et al.
ONCOTARGETS AND THERAPY (2013)
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
Petra Hamerlik et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas
Filip Gabalec et al.
PITUITARY (2012)
Anti-VEGF therapy in pituitary carcinoma
Leon D. Ortiz et al.
PITUITARY (2012)
Estrogen- and xenoestrogen-induced ERK signaling in pituitary tumor cells involves estrogen receptor-α interactions with G protein-αi and caveolin I
Cheryl S. Watson et al.
STEROIDS (2012)
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Chrisostomi Gialeli et al.
FEBS JOURNAL (2011)
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
Hidenori Fukuoka et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
Eduardo Vilar et al.
MOLECULAR CANCER THERAPEUTICS (2011)
HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy
Hidenori Fukuoka et al.
MOLECULAR ENDOCRINOLOGY (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor
Marie S. Thearle et al.
PITUITARY (2011)
Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report
Marcos Paulo Manavela et al.
Pituitary (2011)
Matrix metalloproteinases: Fold and function of their catalytic domains
Cynthia Tallant et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas
Maria Chiara Zatelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Tumor Infiltrating Lymphocytes But Not Serum Pituitary Antibodies Are Associated with Poor Clinical Outcome after Surgery in Patients with Pituitary Adenoma
Isabella Lupi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Membrane-impermeable estrogen is involved in regulation of calbindin-D9k expression via non-genomic pathways in a rat pituitary cell line, GH3 cells
Vu Hoang Dang et al.
TOXICOLOGY IN VITRO (2010)
Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro
Alexander Gorshtein et al.
ENDOCRINE-RELATED CANCER (2009)
Estrogen Receptor-α Mediates the Epidermal Growth Factor-Stimulated Prolactin Expression and Release in Lactotrophs
Nira Ben-Jonathan et al.
ENDOCRINOLOGY (2009)
Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer
Roopali Roy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
ADAMs in cancer cell proliferation and progression
Satsuki Mochizuki et al.
CANCER SCIENCE (2007)
Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line
Isa M. Hussaini et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
International Union of Pharmacology.: LXIV.: Estrogen receptors
Karin Dahlman-Wright et al.
PHARMACOLOGICAL REVIEWS (2006)
Regulation of angiogenesis and invasion by human pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2)
Mohammad T. Malik et al.
MOLECULAR CANCER (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms
Arnab Chakravarti et al.
CLINICAL CANCER RESEARCH (2006)
Intraoperative high-field magnetic resonance imaging in transsphenoidal surgery of hormonally inactive pituitary macroadenomas
Christopher Nimsky et al.
NEUROSURGERY (2006)
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy
C Hunter et al.
CANCER RESEARCH (2006)
Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas
Weiping Liu et al.
JOURNAL OF MEDICAL INVESTIGATION (2005)
Enhanced protein kinase B/Akt signalling in pituitary tumours
M Musat et al.
ENDOCRINE-RELATED CANCER (2005)
Mechanisms of estrogen receptor signaling:: Convergence of genomic and nongenomic actions on target genes
L Björnström et al.
MOLECULAR ENDOCRINOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Raloxifene decreases serum IGF-I in male patients with active acromegaly
EV Dimaraki et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma
T Miyoshi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
Dopamine receptor expression and function in corticotroph pituitary tumors
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Matrix metalloproteinases and tissue inhibitors of metalloproteinases - Structure, function, and biochemistry
R Visse et al.
CIRCULATION RESEARCH (2003)
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue
UJ Knappe et al.
ACTA NEUROPATHOLOGICA (2003)
Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations
LM Coussens et al.
SCIENCE (2002)
ACTH silent adenoma shrinking under cabergoline
P Petrossians et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
